Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Lux Research
Lux Research
Activities:
Media
X
LinkedIn
Trending Articles
Rentschler Biopharma appoints Patrick Cushing as VP Operations for US subsidiary
The novel position will require Dr Cushing to manager operations at the Miford, MA facility in the US
Making the most of each cell: single-use perfusion in biopharma processing
GEA kytero perfusion disk stack separators are pioneering the time- and cost-efficient harvesting of pharmaceutical proteins from cells and facilitating continuous processing,...
Johnson & Johnson submits regulatory application for Tremfya to the European Medicines Agency
The submission included data from the Phase 3 QUASAR programme in ulcerative colitis and the Phase 3 GALAXI programme in Crohn’s disease, which each achieved their primary...
Amolyt receives FDA fast track designation for hypoparathyroidism drug
The therapeutic has been awarded the fast track designation owing to the Phase III Calypso trial, which showed promising efficacy and safety features
Indian government bans three medicines owing to health risks
Decision follows strong stand on suspending marketing of all drugs prohibited for sale in other countries, including the US, UK, EU and Australia
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Media
Transdermal patch delivery technologies will create new blockbuster drugs, says report
Drug delivery via transdermal patches will lead to US$6bn in new annual sales within the next 10 years
Research & Development
China invests billions to catch up with western pharma
China has spent US$160bn on biomedicine, and is poised to surpass Japan to become the second-largest spender on R&D
Media
Fourth-generation biologics set to grow US$120bn market, finds report
Several factors place antibodies at the front of the biologicals wave, says consultancy Lux Research
Media
Big pharma missing out on nanotech opportunities, says report
Pharmaceutical companies have been accused of risking missing the opportunities offered by the latest technological zeitgeist, that of nanotechnology
Subscribe now